Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Clinical Trials to Treat Childhood Embryonal Tumors

Trials 1-6 of 6

A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss
Status: Active
Location: 99 locations
Digoxin for the Treatment of Pediatric and Young Adult Patients with Relapsed Non-SHH, Non-WNT Medulloblastoma
Status: Active
Location: 7 locations
A Peptide Vaccine (PEP-CMV) for the Treatment of Pediatric Patients with Newly Diagnosed High-Grade Glioma and Diffuse Intrinsic Pontine Glioma, or Recurrent, Refractory, or Progressive Medulloblastoma
Status: Active
Location: 5 locations
Genetically Engineered Cells (C7R-GD2.CAR T Cells) for the Treatment of Patients with GD2-Expressing High Grade Glioma or Diffuse Intrinsic Pontine Glioma, The GAIL-B Trial
Status: Active
Location: 2 locations
Cellular Therapy (GPC2-CAR T-Cells) for the Treatment of Children and Young Adults with Relapsed or Refractory Medulloblastoma and other Central Nervous System Embryonal Tumors
Status: Active
Location: Stanford Cancer Institute Palo Alto, Palo Alto, California
Testing the Safety, Tolerability and Immunological Effects of SurVaxM in Children and Young Adults with Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma
Status: Temporarily Closed to Accrual
Location: 13 locations